Close Menu

NEW YORK – A triple-pronged therapy that simultaneously targets BRAF, EGFR, and MEK seems to stretch out overall survival times in BRAF-mutated metastatic colorectal cancer cases, according to results from a randomized Phase III clinical trial called BEACON.

"We're hopeful that this will give new options for our [BRAF-mutated metastatic CRC] patients," said Scott Kopetz, a gastrointestinal medical oncologist at the University of Texas MD Anderson Cancer Center, principal investigator on BEACON and co-lead for MD Anderson's Cancer Moon Shot effort in CRC.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.


This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.